Koji Konomi

Title: Koji Konomi: Innovator in Anti-VEGF Antibody Development

Introduction

Koji Konomi is a notable inventor based in Nara, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of high-affinity antibodies. With a total of 3 patents, Konomi's work focuses on advancing medical treatments through innovative antibody design.

Latest Patents

Konomi's latest patents include the "High-affinity anti-VEGF antibody KLHa505." This invention aims to provide an antibody with significantly high affinity for vascular endothelial growth factor (VEGF) compared to prior art. The monoclonal antibody binds to VEGF with a dissociation constant of 1×10 mol/L or less. Another patent titled "High-affinity anti-VEGF antibody" shares a similar objective, emphasizing the development of antibodies that can effectively target VEGF for therapeutic applications.

Career Highlights

Throughout his career, Konomi has worked with prominent companies in the pharmaceutical industry. He has been associated with Santen Pharmaceutical Co., Ltd. and Order-made Medical Research Inc. His work in these organizations has contributed to advancements in medical research and antibody development.

Collaborations

Konomi has collaborated with esteemed colleagues, including Yasufumi Murakami and Shigeki Mukoubata. These partnerships have fostered innovation and have been instrumental in the progress of his research endeavors.

Conclusion

Koji Konomi's contributions to the field of biotechnology, particularly in the development of high-affinity anti-VEGF antibodies, highlight his role as a significant inventor. His work continues to influence advancements in medical treatments and antibody research.